Analysis of Mycobacterium tuberculosis isolates from treatment failure patients living in East Timor

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 1, 2005, Pages 81-86

  Kelly, P M ^a,e,f   Lumb, R ^b   Pinto, A ^c,d   Da Costa, G ^c,d   Sarmento, J ^c,d   Bastian, I ^b  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c National TB Control Programme   (India)

^d Caritas Dili ^*  (India)

^e CHARLES DARWIN UNIVERSITY   (Australia)

^f NORTHERN TERRITORY DEPARTMENT OF HEALTH   (Australia)

Author keywords

East Timor; Multidrug resistance; Treatment failure; Tuberculosis; VNTR

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; DRUG DOSE REGIMEN; FEMALE; HEALTH PROGRAM; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID HYBRIDIZATION; PREVALENCE; PRIORITY JOURNAL; RADIOMETRY; SPUTUM EXAMINATION; STAINING; TIMOR-LESTE; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MICROBIAL; EAST TIMOR; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 11944258059     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cohn D L, Bustreo F, Raviglione M C. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997; 24 (Suppl 1): S121-130.
2. Bastian I, Rigouts L, van Deun A, Portaels F. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull World Health Organ 2000; 78: 238-251.
3. Espinal M A, Kim S J, Suarez P, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
4. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to anti-tuberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
5. World Health Organization. Anti-tuberculosis drug resistance in the world: Report No 2. Prevalence and trends. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. WHO/CDS/TB/2000.278. Geneva, Switzerland: WHO, 2000.
6. National Tuberculosis Control Programme of Timor Lorosae. TB Control Manual. 2nd ed. Dili, East Timor: Ministry of Health/Caritas Dili, 2001.
7. Enarson D A, Rieder H L, Arnadottir T, Trébucq A. Tuberculosis guide for low income countries. 4th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000.
8. Kent P T, Kubica G P, eds. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, GA: US Department of Health and Human Services, 1985.
9. Metchock B, Nolte F S, Wallace R J Jr. Mycobacterium. In: Murray P R, Baron E J, Pfaller M A, Tenover F C, Yolken R H, eds. Manual of clinical microbiology. 7th ed. Washington, DC: ASM Press, 1999: pp 399-437.
10. Pfyffer G E, Bonato D A, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37: 3179-3186.
11. Heifets L. Conventional methods for antimicrobial susceptibility testing of Mycobacterium tuberculosis. In: Bastian I, Portaels F, eds. Multidrug-resistant tuberculosis. Dordrecht, The Netherlands, Kluwer Academic Publications, 2000: pp 133-143.
12. Frothingham R, Meeker-O'Connell W A. Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats. Microbiology 1998; 144: 1189-1196.
13. Mazars E, Lesjean S, Banuls A-L, et al. High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology. Proc Acad Sciences (USA) 2001; 98: 1901-1906.
14. STATA version 7. College Station, Texas: STATA Corporation, 2001.
15. START version 1.0.5. Keith Jolley. Oxford, UK: University of Oxford, 2000. http://outbreak.ceid.ox.ac.uk/software.htm Accessed January 2004.
16. Tulloch J, Saadah F, de Araujo R M, et al. Initial steps in rebuilding the health sector in East Timor. Washington, DC, USA: The National Academies Press, 2003.
17. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis, 2nd ed. WHO/CDS/TB/2003.320. Geneva, Switzerland: WHO, 2003.
18. Kelly P, Scott L, Krause V. Tuberculosis in East Timorese refugees: implications for health care needs in East Timor. Int J Tuberc Lung Dis 2002; 6: 980-987.
19. Van Deun A, Hamid Salim A, Rigouts L, Rahman M, Fissette K, Portaels F. Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. Int J Tuberc Lung Dis 2001; 5: 329-338.
20. Kritski A L, Rodrigues de Jesus L S, Andrade M K, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997; 111: 1162-1167.
21. Heldal E, Arnadottir T, Cruz J R, Tardencilla A, Chacon L. Low failure rate in standardised retreatment of tuberculosis in Nicaragua: patient category, drug resistance and survival of 'chronic' patients. Int J Tuberc Lung Dis 2001; 5: 129-136.
22. Glynn J R, Whitely J, Bifani P J, Kremer K, van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: A systematic review. Emerg Infect Dis 2002; 8: 843-849.
23. Farmer P. The major infectious diseases in the world - to treat or not to treat? N Engl J Med 2001; 345: 208-210.
24. World Health Organization. Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). WHO/CDS/TB/2000.279. Geneva, Switzerland: WHO, 2000.